Purpose - Drawing from legitimacy and institutional entrepreneurship theory, this study assesses the naming patterns of entrepreneurial firms in the US biotechnology industry. Design/methodology/approach - The authors use a mixed-methods design of content analysis and regression to analyze a...

The UK National Stem Cell Network (UKNSCN) provided the stem cell community with regular digests of both published patent applications and granted patents in the field of stem cells.This report provides an updated patent landscape overview for the period 1 November 2008 to 31 October 2011 with a...

Innovation most successfully occurs in regions around the world that allow inventors to operate in a public policy framework that rewards risk taking and investment. This is especially so for the biopharmaceutical industry. Because of the high risk, high cost, and long research timelines...

Biotechnology is a field which is utterly dependent on knowledge creation and management of novel innovations which are an outcome of contemporary knowledge. Knowledge management is a prime factor which determines the success or failure of a biotechnology company competing in the global...

Surfactants are amphiphilic compounds having both hydrophobic as well as hydrophilicmoieties. They tend to possess surface active characteristics by decreasing the surface tensionbetween the interfaces. Generally, a molecule of surfactant consists of a lipophilic group,usually a long-chain...

The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered (or self-administered) to patients, intending to cure them, vaccinate them, or alleviate the symptoms. Pharmaceutical companies may deal in generic or...

The paper at hand provides deep insights into the development of the German bioeconomy at the municipality level. The aim was to find out which determinants play a role in the location of bioeconomy patents at the municipality level and to analyze the respective stages of the bioeconomy in the...

Confronted with new global competitive environment, rising R&D costs, growing integration of different technologies, shorter life cycles, and increased pace of innovation, high-tech companies increasingly collaborate with external partners. Innovation networks became unconditional driver of...

Whether it is a government research institution, a public-private partnership, or a private enterprise, the South African biotechnology industry requires funding for the biotechnology industry. Our goal with this research is to look into the role of venture capital (VC) in financing biotech...

The rapid advancement of technologies has opened a wide array of possibilities for us. Once engineering, which was limited to machines and other related abiotic segments, has seen some major developments, and now we can modify or genetically engineer living organisms. This new branch of science...

Considerable evidence suggests that information is acquired more easily within than across firm boundaries. I explore why this is observed in the setting of clinical development. Since the mid-1980s, pharmaceutical firms have partly contracted out the operational aspects of clinical trials to...

We examine how two highly successful new biotechnology firms (NBFs) source their most critical input -- scientific knowledge. We find that scientists at the two NBFs enter into large numbers of collaborative research efforts with scientists at other organizations, especially universities. Formal...

Population ecology models are elegant in form and adequate in describing aggregate data, but poor in telling stories and predicting the location of growth. Fundamentals models emphasizing the variables central to resource mobilization, such as intellectual human capital, can predict where and...

The past decade has seen rapid development of the bioeconomy in the Nordic region. Consequently, the composition of sectors that intervene in the concept of bioeconomy serves as a powerful, progressive, and pure engine, which creates and drives market opportunities across various industries,...

This paper analyzes stock returns for biotechnology firms after initial public offering (IPO) and explores the effect of social media-specifically, Twitter-on these returns. The results indicate positive yet insignificant cumulative average abnormal returns (CAARs) of 1.97% in the first 25 days...

Many governments have established cluster policies to foster innovation and support hightech industries through agglomeration economies. They attempt to boost networks through providing clusters with resources to organise heterogeneous support activities. A key question is which support...

In this paper, we examine the determinants of control rights in technology strategic alliances between biotechnology firms and pharmaceutical corporations, as well as with other biotechnology firms. We undertake three clinical studies and an empirical analysis of 200 contracts. Consistent with...

Advance of science and its commercial applications are in a close, symbiotic relationship in the U.S. biotechnology industry. Comparing Japan and the U.S., the structure of the science appears broadly similar, but the organization of the biotechnology industry is quite dissimilar. In the U.S.,...

Using data on over 900 firms for the period 1988-2000, we estimate the effect on phase-specific biotech and pharmaceutical R&D success rates of a firm's overall experience, its experience in the relevant therapeutic category; the diversification of its experience, and alliances with large and...

A European Commission report into patent licensing (Radauer and Dudenbostel 2013) concluded that the technology industry out-licenses more non-core patents than the pharmaceutical industry. A literature review suggests that this variation may be due to the perceived risks associated with holding...

Modern crop biotechnology is being considered as a novel solution to the long-standing problems of food insecurity, low crop productivity, pest and disease prevalence, and micronutrient deficiency, particularly in developing and climate-vulnerable economies. Empirical evidence of its benefits...

There’s a longstanding adage in the biopharma industry that biotech initial public offering (IPO) windows creak open but slam shut. After seven years of capital markets being receptive to biotech public financings, one might have predicted that the industry’s IPO window would be a casualty...

The purpose of this research is to explore the internationalization behavior of BioTech firms producing a COVID 19 vaccine using the Born Global internationalization model as a conceptual framework. The research methodology that has been considered in this study is a qualitative, multiple-case...

The interaction between product market competition, R&D investment, and the financing choices of R&D-intensive firms on the development of innovative products is only partially understood. To motivate empirical hypotheses about this interaction, we develop a model which predicts that as...

High volatility, no predictable cash flows and technological uncertainties make Biotech-Healthcare companies’ valuation a challenging task for analysts and investors. Translating clinical promises into economic value represents a rough obstacle of this attractive business, especially in...

Commercializing knowledge involves transfer from discovering scientists to those who will develop it commercially. New codes and formulae describing discoveries develop slowly - with little incentive if value is low and many competing opportunities if high. Hence new knowledge remains naturally...

We examine the relationship between the intellectual capital of scientists making frontier discoveries, the presence of great university bioscience programs, the presence of venture capital firms, other economic variables, and the founding of U.S. biotechnology enterprises during 1976-1989....

A rich literature argues that interorganizational networks foster learning and coordinated adaptation among their constituents, but embedded ties between organizations are not ubiquitous. What explains this heterogeneity? Acknowledging the influence of agency relationships within organizations...

In today's modern world, the impact of technology can be felt strongly. Technology has both improved life and contributed immensely to the GDP of a lot of countries. The benefit of technological advancement across several segments of society is likely to continue. However Africa is yet to...

The article is devoted to the study of the concepts of biotechnology and biopatent. Their scientific definitions are offered, the classification of the directions of biotechnologies is given. The paper analyzes the state of patenting of biotechnological inventions in our country. A comparative...

How much forward-looking information do public companies disclose, including on ESG themes? Do they provide targets and KPIs on themes key to long-term value creation? In this paper, we analyze the accessibility, quantity, and time frame of forward-looking information disclosed by the 25...

The purpose of this multiple case study is to explore the internationalization processes, patterns, and behaviours of BioTech firms producing a COVID-19 vaccine using the Biotechnology international new ventures (BioTech INVs) model as a conceptual framework. The sample consists of eight BioTech...

We examine the effect of the Jumpstart Our Business Startups (JOBS) Act on biotech startups, who conduct almost 40% of IPOs since 2012. Reduced compliance costs encourage innovation capital formation as biotech IPO volume increases 200% and proceeds rise by 30%. After the JOBS Act, biotech...

In the current COVID-19 pandemic, we witness sharp fluctuations of biopharmaceutical equity prices as a response to innovation related news. On 23.04.2020, the stock price of Biotech firm Gilead Sciences fell by as much as 9% after rumors suggested that remdesivir, its experimental COVID-19...

In this research, we analyze the influence of two alliance management capabilities, coordination and interorganizational learning, on the performance of alliances for innovation. By adopting a contingency view, we explore whether the effectiveness of these capabilities depends on certain...